Investor relations
SCILEX Pharmaceuticals specializes in manufacturing branded treatments to manage acute and chronic pain.
CONTACTS
SCILEX Pharmaceuticals, Inc.
(844) SCILEX1
WPedranti@scilexpharma.com
SCILEX news
Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018
SAN DIEGO, September 19, 2018 – Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Scilex expects commercial availability of ZTlido through wholesale distribution in …
Upcoming events
We’re keeping busy at SCILEX. See where we’ll be next.
Current partnerships
Strong relationships yield promising results. That’s why we’ve cultivated partnerships with some of the best minds in the business. As part of our strategy, SCILEX calls on industry leaders to assist the management team in innovating, manufacturing, developing, marketing, and selling novel products and technologies. Here’s just a sample of the notable partners across all sectors of the pharmaceutical industry with whom we collaborate.
- Beckloff Associates Cardinal Health
cGMP Regulatory - Clinipace Worldwide
CRO, Regulatory - Foley & Lardner
FDA Counsel - ITOCHU CHEMICAL FRONTIER Corporation
ICF, Tokyo, Japan - Real Regulatory
EU Regulatory
